NCT03878121View on ClinicalTrials.gov

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

October 15, 2025

Study Completion Date

October 15, 2025

Conditions
Healthy Volunteer
Interventions
BIOLOGICAL

Ad4-Env145NFL

10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.

BIOLOGICAL

Ad4-Env150KN

10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.

BIOLOGICAL

VRC-HIVRGP096-00-VP (Trimer 4571) with alum

500-mcg dose of protein boost vaccine formulated for intramuscular administration.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH